BOSTON ( TheStreet) -- Welcome 2010! To get the year started, here's a calendar of important, potentially stock-moving biotech events for January:

Jan. 7
Forest Labs ( FRX) investor/analyst meeting.
Teva Pharmaceuticals ( TEVA) investor/analyst meeting.

Jan. 10-14
28th Annual J.P. Morgan Healthcare Conference.

Jan. 11
Food and Drug Administration advisory committee meeting for Forest Labs' Bystolic in congestive heart failure.

Jan. 11-14
International Association for the Study of Lung Cancer meeting.

Jan. 14
Ilumina ( ILMN) investor/analyst meeting.

Jan. 16
FDA approval decision date for Mannkind's ( MNKD) Afresa, an inhaled insulin for diabetes.

Jan. 18
FDA approval decision date for OSI Pharmaceuticals' ( OSIP) Tarceva in first-line (maintenance) non-small cell lung cancer.

Jan. 22
FDA approval decision date for Acorda Therapeutics' ( ACOR) Amaya for multiple sclerosis

Jan. 22-24
American Society for Clinical Oncology Gastrointestinal Cancers Symposium.

Important clinical trials with potential data readouts or other biotech events expected in January:

Spectrum Pharmaceuticals ( SPPI) meeting with FDA to discuss complete response letter for colon cancer drug Fusilev.

FDA approval decision for Novo Nordisk's ( NVO) diabetes drug Victoza.

FDA approval decision for Auxillium Pharmaceuticals' ( AUXL) Xiaflex for Dupuytren's Contracture. (With Pfizer ( PFE) as marketing partner.)

Synta Pharmaceuticals ( SNTA) --
Results from a phase II study of apilimod in rheumatoid arthritis.

-- Reported by Adam Feuerstein in Boston.
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

S&P 500 and Dow Score Records With Wall Street Upbeat Ahead of Fed

S&P 500 and Dow on Track for Records With Markets in Good Mood Ahead of Fed

S&P 500 and Dow Aim for New Records With Broad-Based Gains Ahead of Fed

Dow and S&P 500 Reach New Intraday Highs With Markets in Good Mood Ahead of Fed

Teva's New CEO Brings This Secret Weapon